| InVitria's Cellastim Delivers Superior Results in CHO Cell Culture Cellastim, an animal-free recombinant albumin product manufactured by InVitria, can outperform animal and human derived serum in CHO cell culture. Fort Collins, CO (PRWEB) December 3, 2008 -- Cellastim has proven to be a robust replacement for serum derived albumin in CHO media and can improve both the growth kinetics and productivity of CHO cell lines across a variety of chemically defined media. Studies support InVitria's claim that its Cellastim [http://www.cellastim.com] outperforms other chemically defined cell culture ingredients and can be used by the biopharmaceutical, mammalian cell culture, stem cell and regenerative medicine industries as a supplement for cell culture media. Cellastim is a defined supplement that can enhance performance of chemically defined media. One study revealed that Cellastim outperformed plasma-derived human serum albumin with a 50% average increase in productivity in several chemically defined cell culture media. "InVitria's Cellastim helps optimize cell culture media performance safely and effectively," said InVitria President Scott Deeter. "As a regulatory friendly product, Cellastim can provide researchers an option to free their cells from the risk of potentially harmful contaminants, while simultaneously enhancing cell growth and productivity." The conversion from serum supplemented media to serum-free media for production of biopharmaceuticals in CHO cells is essential for the elimination of all animal components in the culturing media. The addition of InVitria's Cellastim offers optimal defined quality and safety for the production of biopharmaceuticals in CHO cells. About InVitria For more information about InVitria's products or to place an order, please contact InVitria's sales and marketing team by e-mail or phone. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Phone: 1-800-916-8311
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
